Bezisterim
| Clinical data | |
|---|---|
| Other names | NE3107; NE-3107; HE3286; HE-3286; 17α-Ethynyl-5-androstene-3β,7β,17β-triol; |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H30O3 |
| Molar mass | 330.468 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Bezisterim (developmental code names NE3107, HE3286) is a synthetic analogue of androstenetriol that is believed to have anti-inflammatory and insulin-sensitizing effects in the brain.[1] The compound crosses the blood–brain barrier and does not activate any neurotransmitter receptors.[2] It has been tested as a treatment for Alzheimer's disease,[3][4][5][6] Parkinson's disease,[1] and traumatic brain injury.[7] The drug is under development for a variety of conditions and its highest developmental phase is phase 3 for Alzheimer's disease.[1]
See also
- List of investigational cognition and memory disorder drugs
- List of investigational Parkinson's disease drugs
References
- ^ a b c "Bezisterim". AdisInsight. 5 September 2024. Retrieved 26 September 2024.
- ^ Reading, Chris L; Ahlem, Clarence N; Parameswaran, Narayanan (December 2021). "Rationale for an anti-inflammatory insulin sensitizer in a phase 3 Alzheimer's disease trial". Alzheimer's & Dementia. 17 (S9). doi:10.1002/alz.057438.
- ^ Stoiljkovic, Milan; Horvath, Tamas L.; Hajós, Mihály (July 2021). "Therapy for Alzheimer's disease: Missing targets and functional markers?". Ageing Research Reviews. 68 101318. doi:10.1016/j.arr.2021.101318. PMC 8131215. PMID 33711510.
- ^ Balzano, Tiziano; Esteban-García, Noelia; Blesa, Javier (2 January 2023). "Neuroinflammation, immune response and α-synuclein pathology: how animal models are helping us to connect dots". Expert Opinion on Drug Discovery. 18 (1): 13–23. doi:10.1080/17460441.2023.2160440. PMID 36538833. S2CID 254959175.
- ^ Liu, Ping; Wang, Yunyun; Sun, Yan; Peng, Guoping (April 2022). "Neuroinflammation as a Potential Therapeutic Target in Alzheimer's Disease". Clinical Interventions in Aging. 17: 665–674. doi:10.2147/CIA.S357558. PMC 9064449. PMID 35520949.
- ^ Xi, Yilong; Chen, Yun; Jin, Yi; Han, Guochen; Song, Mingjie; Song, Tingting; Shi, Yang; Tao, Ling; Huang, Zewei; Zhou, Jianping; Ding, Yang; Zhang, Huaqing (May 2022). "Versatile nanomaterials for Alzheimer's disease: Pathogenesis inspired disease-modifying therapy". Journal of Controlled Release. 345: 38–61. doi:10.1016/j.jconrel.2022.02.034. PMID 35257810. S2CID 247285338.
- ^ "U.S. Clinical Trial: Neurological Associates of West Los Angeles Listed a New Clinical Trial to Study Insulin-sensitizing NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury." Contify Life Science News, 1 Aug. 2023, p. NA. Gale OneFile: Health and Medicine, link.gale.com/apps/doc/A759542006/HRCA?u=anon~bb46c85&sid=sitemap&xid=0c315c7e. Accessed 14 Dec. 2023.
Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.